SD221102-001 page 1 of 3

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368

Sample Ghost - Proprietary Blend

| Ç |)A] | ſesti | ng |
|---|------|-------|----|
| | | | |



| Sample ID SD221102-001 (54368) | Matrix Concentrate (Inhalable Cannabis Good) | | | | | | |
|--|--|-----------------------------|-------------------------|--|--|--|--|
| Distributor License 604034860 | Address 1 Va | Inderbilt, Irvine CA, 92618 | Name Savage Enterprises | | | | |
| Sampled - | Received Nov 01, 2022 | | Reported Nov 07, 2022 | | | | |
| Analyses executed CANX, RES, MIBIG, MTO, PES, HME, FVI | | | | | | | |

Laboratory note: The estimated concentration of the unknown peak in the sample is 8.93% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)d8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC. (+)d8-THC is a different compound from the main (-)d8-THC cannabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC and d9-THC and d9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)d8-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 Concentration is estimated to be 65.97%

CANX - Cannabinoids Analysis

Analyzed Nov 07, 2022 | Instrument HLPC Measurement Uncertainty at 95% confidence7.806%

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|--|-------------|-------------|-------------|----------------|
| 11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiorcin (CBDO) | 0.002 | 0.007 | ND | ND |
| Abnormal Cannabidiorcin (a-CBDO) | 0.01 | 0.031 | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) | 0.012 | 0.036 | ND | ND |
| 11-Hydroxy-∆8-Tetrahydrocannabinol (11-Hyd-∆8-THC) | 0.007 | 0.021 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| 1(S)-THD (s-THD) | 0.013 | 0.041 | ND | ND |
| 1(R)-THD (r-THD) | 0.025 | 0.075 | ND | ND |
| Tetrahydrocannabivarin (THCV) | 0.001 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabivarin (Δ8-THCV) | 0.021 | 0.064 | ND | ND |
| Tetrahydrocannabutol (Δ9-THCB) | 0.013 | 0.038 | 3.42 | 34.17 |
| Cannabinol (CBN) | 0.001 | 0.16 | 6.35 | 63.49 |
| exo-THC (exo-THC) | 0.016 | 0.8 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | UI | UI |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | 63.97 | 639.75 |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.16 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.16 | ND | ND |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.16 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.16 | ND | ND |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | ND | ND |
| Δ9-Tetrahydrocannabihexol (Δ9-THCH) | 0.024 | 0.071 | 0.92 | 9.23 |
| Cannabinol Acetate (CBNO) | 0.014 | 0.043 | ND | ND |
| Δ9-Tetrahydrocannabiphorol (Δ9-THCP) | 0.017 | 0.16 | 2.54 | 25.43 |
| $\Delta 8$ -Tetrahydrocannabiphorol ($\Delta 8$ -THCP) | 0.041 | 0.16 | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.16 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.031 | 0.094 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.16 | 1.55 | 15.55 |
| 9(R)-HHCP (r-HHCP) | 0.026 | 0.079 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.067 | 0.204 | 0.69 | 6.88 |
| Total THC (THCa * 0.877 + Δ9THC) | | | ND | ND |
| Total THC + Δ 8THC + Δ 10THC (THCa * 0.877 + Δ 9THC + Δ 8THC + Δ 10THC) | | | 63.97 | 639.75 |
| Total CBD (CBDa * 0.877 + CBD) | | | ND | ND |
| Total CBG (CBGa * 0.877 + CBG) | | | ND | ND |
| Total HHC (9r-HHC + 9s-HHC) | | | ND | ND |
| Total Cannabinoids | | | 79.45 | 794.51 |

HME - Heavy Metals Detection Analysis

| Analyzed Nov 04, 2022 | Instrument ICP/MSMS | Method SOP-005 |
|-----------------------|---------------------|----------------|
| | | |

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|--------------|-------------|-------------|---|---------------|--------------|-------------|-------------|---------------------------------|---------------|
| Arsenic (As) | 0.0002 | 0.0005 | <loq< td=""><td>0.2</td><td>Cadmium (Cd)</td><td>3.0e-05</td><td>0.0005</td><td><loq< td=""><td>0.2</td></loq<></td></loq<> | 0.2 | Cadmium (Cd) | 3.0e-05 | 0.0005 | <loq< td=""><td>0.2</td></loq<> | 0.2 |
| Mercury (Hg) | 1.0e-05 | 0.0001 | ND | 0.1 | Lead (Pb) | 1.0e-05 | 0.00125 | <loq< td=""><td>0.5</td></loq<> | 0.5 |

MIBIG - Microbial Testing Analysis

| Analyzed Nov 04, 2022 | Instrument qPCR and/or Plating | Method SOP-007 |
|-----------------------|--------------------------------|----------------|
| | | |

| Analyte | Result CFU/g | Limit | Analyte | Result CFU/g | Limit |
|--|-----------------|---------------|---------------------|-----------------|---------------|
| Shiga toxin-producing Escherichia Coli | ND | ND per 1 gram | Salmonella spp. | ND | ND per 1 gram |
| Aspergillus fumigatus | ND | ND per 1 gram | Aspergillus flavus | ND | ND per 1 gram |
| Aspergillus niger | ND | ND per 1 gram | Aspergillus terreus | ND | ND per 1 gram |

UI Not Identified ND Not Detected N/A Not Applicable DI Dimit of Detection LOQ Limit of Quantification <LOQ Detected NUCL Above upper limit of linearity >ULCL Above upper limit of linearity CFU/Q Colong Forming Units per 1 gram TNTC Too Numerous to Count







Authorized Signature

Brandon Starr



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 "This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Foll status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Foll evolution unless excellation unsite savelitht unsult state or local lows and has been reported, and and unsult is developed unon request.

SD221102-001 page 2 of 3

QA Testing

MTO - Mycotoxin Testing Analysis

Analyzed Nov 03, 2022 | Instrument LC/MSMS | Method SOP-004

| ······· | | | | | | | | | |
|--------------|--------------|--------------|-----------------------|----------------|------------------|--------------|--------------|-----------------------|----------------|
| Analyte | LOD ug/kg | LOQ ug/kg | Result ug/kg (ppb) | Limit ug/kg | Analyte | LOD ug/kg | LOQ ug/kg | Result ug/kg (ppb) | Limit ug/kg |
| Ochratoxin A | 5.0 | 20.0 | ND | 20 | Aflatoxin B1 | 2.5 | 5.0 | ND | - |
| Aflatoxin B2 | 2.5 | 5.0 | ND | - | Aflatoxin G1 | 2.5 | 5.0 | ND | - |
| Aflatoxin G2 | 2.5 | 5.0 | ND | - | Total Aflatoxins | 10.0 | 20.0 | ND | 20 |

UI Not Identified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected NUCU. Above upper limit of linearity >ULCU. Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count







Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Mon, 07 Nov 2022 18:05:48 -0800



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1
This report shall not be reprodued except in full, without the written approval of the lab. This report is for informational purposes only and should not be used for diagnose, treat or prevent ory disease. Results are only for samples and batches indicated. Results are reported on Poss/Follevolution unless explicitly repared by one classing in and indicated in the Poss/Follevolution unless explicitly repared by and the batches indicated in the Indicated in the Poss/Follevolution unless explicitly one request.

SD221102-001 page 3 of 3

QA Testing

PES - Pesticides Screening Analysis

Analyzed Nov 03, 2022 | Instrument LC/MSMS GC/MSMS | Method SOP-003

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|-------------------------|-------------|-------------|----------------|---------------|-----------------------|-------------|-------------|----------------|---------------|
| Aldicarb | 0.0078 | 0.02 | ND | 0.0078 | Carbofuran | 0.01 | 0.02 | ND | 0.01 |
| Dimethoate | 0.01 | 0.02 | ND | 0.01 | Etofenprox | 0.02 | 0.1 | ND | 0.02 |
| Fenoxycarb | 0.01 | 0.02 | ND | 0.01 | Thiachloprid | 0.01 | 0.02 | ND | 0.01 |
| Daminozide | 0.01 | 0.03 | ND | 0.01 | Dichlorvos | 0.02 | 0.07 | ND | 0.02 |
| Imazalil | 0.02 | 0.07 | ND | 0.02 | Methiocarb | 0.01 | 0.02 | ND | 0.01 |
| Spiroxamine | 0.01 | 0.02 | ND | 0.01 | Coumaphos | 0.01 | 0.02 | ND | 0.01 |
| Fipronil | 0.01 | 0.1 | ND | 0.01 | Paclobutrazol | 0.01 | 0.03 | ND | 0.01 |
| Chlorpyrifos | 0.01 | 0.04 | ND | 0.01 | Ethoprophos (Prophos) | 0.01 | 0.02 | ND | 0.01 |
| Baygon (Propoxur) | 0.01 | 0.02 | ND | 0.01 | Chlordane | 0.04 | 0.1 | ND | 0.04 |
| Chlorfenapyr | 0.03 | 0.1 | ND | 0.03 | Methyl Parathion | 0.02 | 0.1 | ND | 0.02 |
| Mevinphos | 0.03 | 0.08 | ND | 0.03 | Abamectin | 0.03 | 0.08 | ND | 0.1 |
| Acephate | 0.02 | 0.05 | ND | 0.1 | Acetamiprid | 0.01 | 0.05 | ND | 0.1 |
| Azoxystrobin | 0.01 | 0.02 | ND | 0.1 | Bifenazate | 0.01 | 0.05 | ND | 0.1 |
| Bifenthrin | 0.02 | 0.35 | ND | 3 | Boscalid | 0.01 | 0.03 | ND | 0.1 |
| Carbaryl | 0.01 | 0.02 | ND | 0.5 | Chlorantraniliprole | 0.01 | 0.04 | ND | 10 |
| Clofentezine | 0.01 | 0.03 | ND | 0.1 | Diazinon | 0.01 | 0.02 | ND | 0.1 |
| Dimethomorph | 0.02 | 0.06 | ND | 2 | Etoxazole | 0.01 | 0.05 | ND | 0.1 |
| Fenpyroximate | 0.02 | 0.1 | ND | 0.1 | Flonicamid | 0.01 | 0.02 | ND | 0.1 |
| Fludioxonil | 0.01 | 0.05 | ND | 0.1 | Hexythiazox | 0.01 | 0.03 | ND | 0.1 |
| Imidacloprid | 0.01 | 0.05 | ND | 5 | Kresoxim-methyl | 0.01 | 0.03 | ND | 0.1 |
| Malathion | 0.01 | 0.05 | ND | 0.5 | Metalaxyl | 0.01 | 0.02 | ND | 2 |
| Methomyl | 0.02 | 0.05 | ND | 1 | Myclobutanil | 0.02 | 0.07 | ND | 0.1 |
| Naled | 0.01 | 0.02 | ND | 0.1 | Oxamyl | 0.01 | 0.02 | ND | 0.5 |
| Permethrin | 0.01 | 0.02 | ND | 0.5 | Phosmet | 0.01 | 0.02 | ND | 0.1 |
| Piperonyl Butoxide | 0.02 | 0.06 | ND | 3 | Propiconazole | 0.03 | 0.08 | ND | 0.1 |
| Prallethrin | 0.02 | 0.05 | ND | 0.1 | Pyrethrin | 0.05 | 0.41 | ND | 0.5 |
| Pyridaben | 0.02 | 0.07 | ND | 0.1 | Spinosad A | 0.01 | 0.05 | ND | 0.1 |
| Spinosad D | 0.01 | 0.05 | ND | 0.1 | Spiromesifen | 0.02 | 0.06 | ND | 0.1 |
| Spirotetramat | 0.01 | 0.02 | ND | 0.1 | Tebuconazole | 0.01 | 0.02 | ND | 0.1 |
| Thiamethoxam | 0.01 | 0.02 | ND | 5 | Trifloxystrobin | 0.01 | 0.02 | ND | 0.1 |
| Acequinocyl | 0.02 | 0.09 | ND | 0.1 | Captan | 0.01 | 0.02 | ND | 0.7 |
| Cypermethrin | 0.02 | 0.1 | ND | 1 | Cyfluthrin | 0.04 | 0.1 | ND | 2 |
| Fenhexamid | 0.02 | 0.07 | ND | 0.1 | Spinetoram J,L | 0.02 | 0.07 | ND | 0.1 |
| Pentachloronitrobenzene | 0.01 | 0.1 | ND | 0.1 | | | | | |

RES - Residual Solvents Testing Analysis

Analyzed Nov 07, 2022 | Instrument GC/FID with Headspace Analyzer | Method SOP-006

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|----------------------------|-------------|-------------|--|---------------|------------------------------|-------------|-------------|----------------|---------------|
| Propane (Prop) | 0.4 | 40.0 | ND | 5000.0 | Butane (But) | 0.4 | 40.0 | ND | 5000.0 |
| Methanol (Metha) | 0.4 | 40.0 | ND | 3000.0 | Ethylene Oxide (EthOx) | 0.4 | 0.8 | ND | 1.0 |
| Pentane (Pen) | 0.4 | 40.0 | ND | 5000.0 | Ethanol (Ethan) | 0.4 | 40.0 | ND | 5000.0 |
| Ethyl Ether (EthEt) | 0.4 | 40.0 | ND | 5000.0 | Acetone (Acet) | 0.4 | 40.0 | ND | 5000.0 |
| Isopropanol (2-Pro) | 0.4 | 40.0 | ND | 5000.0 | Acetonitrile (Acetonit) | 0.4 | 40.0 | ND | 410.0 |
| Methylene Chloride (MetCh) | 0.4 | 0.8 | ND | 1.0 | Hexane (Hex) | 0.4 | 40.0 | ND | 290.0 |
| Ethyl Acetate (EthAc) | 0.4 | 40.0 | ND | 5000.0 | Chloroform (Clo) | 0.4 | 0.8 | ND | 1.0 |
| Benzene (Ben) | 0.4 | 0.8 | ND | 1.0 | 1-2-Dichloroethane (12-Dich) | 0.4 | 0.8 | ND | 1.0 |
| Heptane (Hep) | 0.4 | 40.0 | <loq< td=""><td>5000.0</td><td>Trichloroethylene (TriClEth)</td><td>0.4</td><td>0.8</td><td>ND</td><td>1.0</td></loq<> | 5000.0 | Trichloroethylene (TriClEth) | 0.4 | 0.8 | ND | 1.0 |
| Toluene (Toluene) | 0.4 | 40.0 | ND | 890.0 | Xylenes (Xyl) | 0.4 | 40.0 | ND | 2170.0 |

FVI - Filth & Foreign Material Inspection Analysis

Analyzed Nov 01, 2022 | Instrument Microscope | Method SOP-010 Analyte / Limit Result Analyte / Limit Result > 1/4 of the total sample area covered by sand, soil, cinders, or dirt > 1/4 of the total sample area covered by mold ND ND >1 insect fragment, 1 hair, or 1 count mammalian excreta per 3g > 1/4 of the total sample area covered by an imbedded foreign material ND ND

UI Not Identified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected NUCU. Above upper limit of linearity >ULCU. Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count







Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Mon, 07 Nov 2022 18:05:48 -0800



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "os received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evolution unless explicitude, state or including and accordance with federal or should not be upon request.